Mertansine (DM1) refers to the thiol-containing maytansinoid, DM1 (N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) attached to a monoclonal antibody through reaction of the thiol group with the SPP (N-succinimidyl 4-(2-pyridyldithio)) linker to create an antibody-drug conjugate or ADC. Experimental ADCs with the SPP-DM1 design include lorvotuzumab mertansine.

SMCC-DM1 (DM1-SMCC) (DM1-SMCC) is a drug-linker conjugate which composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody-drug conjugate (ADC).

Val-cit-PAB-OH is an ADC linker that is cleavable.

Boc-C16-COOH is a alkyl-chain-based PROTAC linker. Boc-C16-COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Fmoc-Val-Cit-PAB is a linker for antibody-drug-conjugation (ADC).

MC-Gly-Gly-Phe is a cleavable linker. MC-Gly-Gly-Phe can be used for antibody-drug conjugates (ADC).

PC Biotin-PEG3-alkyne is an ADC linker, cleavable 3-unit PEG, which can also be used to synthesize antibody drug conjugates (ADCs).

MFCD28987368 is a degradable ADC linker that can be used in the synthesis of antibody coupled drugs (ADCs).

N3-C4-NHS ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Fmoc-Ala-Ala-Asn(Trt)-OH is a cleavable linker vital in ADC synthesis. Fmoc-Ala-Ala-Asn(Trt)-OH joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC).. CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. .

Hydroxy-PEG10-acid (HO-PEG10-CH2CH2COOH) is a PEG-based PROTAC linker that can be used to synthesize PROTACs[1].

Mal-PEG1-Val-Cit-OH is a cleavable one-unit polyethylene glycol (PEG) linker employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Fmoc-PEA (Example 1-2) is a used as a cleavable linker for antibody-drug conjugates (ADC).

SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy.

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker employed in the synthesis of ADCs[1].

Mal-VC-PAB-DM1, a drug-linker conjugate for antibody-drug conjugates (ADCs), exhibits potent antitumor activity. It incorporates DM1, a potent microtubule-disrupting agent, connected through the ADC linker Mal-VC-PAB [1].

Doxorubicin-SMCC is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Sq-Cit-PAB-Dolastatin10 is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), utilizing Dolastatin10 (a tubulin polymerization inhibitor) connected through the MC-Sq-Cit-PAB ADC linker.

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound resulting from the conjugation of monomethyl auristatin E (MMAE), a potent tubulin inhibitor serving as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

Amino-Tri-(carboxyethoxymethyl)-methane hydrochloride is a cleavable PEG-based linker employed in the synthesis of antibody-drug conjugates (ADCs) and utilized as a PEG-based PROTAC linker for PROTACs synthesis, as documented in references [1] [2].

Aminooxy-amido-PEG4-propargyl is a 4-unit PEG ADC linker that is non-cleavable and specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

NH-bis(C1-Boc)is a uncleavable linker. NH-bis can be used for antibody-drug conjugates (ADC).

NHPI-PEG3-C2-NHS ester is a three-unit PEG linker compound, noncleavable in nature, specifically employed in the synthesis of antibody-drug conjugates (ADCs).

β-Estradiol-6-CMO-PEG3-biotin serves as a cleavable 3-unit PEG ADC linker for the synthesis of antibody-drug conjugates (ADCs)[1].

Propargyl-PEG1-SS-PEG1-PFP ester is a cleavable linker consisting of a 1-unit polyethylene glycol (PEG) backbone, designed for use in the synthesis of antibody-drug conjugates (ADCs)[1].

Azido-PEG4-C2-acid, a PEG-based PROTAC linker, is utilized in the synthesis of vRucaparib-TP4. It serves as a non-cleavable 4 unit PEG ADC linker for antibody-drug conjugate (ADC) synthesis.

Ald-Ph-NHS ester is a non-cleavable linker used in antibody-drug-conjugation (ADC).

Boc-Val-Ala-PAB-PNP is an ADC linker employed for the synthesis of antibody-drug conjugates (ADCs)[1]. This cleavable compound efficiently facilitates the attachment of drugs to antibodies, allowing for targeted delivery and release of therapeutic agents within the body, making it an important component in ADC development.

DBCO acid 2 is a Click Chemistry intermidate used for antibody-drug conjugates.

Propargyl-C1-NHS ester (4-Pentynoic Acid Succinimidyl Ester) is a nonclaevable linker used for antibody-drug-conjugation (ADC).

Fmoc-Asp-NH2 is a cleavable ADC linker. Fmoc-Asp-NH2 can be used in the synthesis of antibody-drug conjugates (ADCs).

MAC glucuronide linker-1 is a nonclaevable ADC linker for antibody-drug-conjugations (ADCs).

Oleoyl-Gly-Lys-N-(m-PEG11) is a cleavable 11 unit PEG linker utilized for the synthesis of antibody-drug conjugates (ADCs)[1].

Fluorescein-DBCO is a non-cleavable linker employed for synthesizing antibody-drug conjugates (ADCs) [1].

MAL-PEG4-MMAF is a maleimido functionalized derivative of MMAF (Monomethyl auristatin F) with PEG4 linker. The maleimido functional group can be easily conjugated to protein carriers (such as antibody or enzyme). MAL-PEG4-MMAF is a useful precursor for ma

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.

NAMPT inhibitor-linker 1, a drug-linker conjugate for ADC, integrates an NAMPT inhibitor (as a payload) with a linker. In the formulation of ADC-3, it pairs with an anti-c-Kit monoclonal antibody, demonstrating strong efficacy against c-Kit expressing cell lines, specifically GIST-T1 and NCI-H526, where it exhibits IC50 values of <3 pM and 9 pM, respectively.

MC-GGFG-DX8951 is a drug-linker conjugate designed for antibody-drug conjugation (ADC) that demonstrates antitumor activity through the deployment of DX8951, a DNA topoisomerase I inhibitor, connected using the protease-cleavable MC-GGFG linker[1].

MAL-di-EG-Val-Cit-PAB-MMAE comprises the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, which are essential components of antibody-drug conjugates (ADCs).

MC-VC-PABC-DNA31 is a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC) that demonstrates potent antitumor activity. It employs DNA31, an effective inhibitor of RNA polymerase, connected through the MC-VC-PABC ADC linker.

MC-Val-Cit-PAB-Indibulin is an antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), featuring the orally active tubulin assembly inhibitor, Indibulin, connected through the MC-Val-Cit-PAB ADC linker. This compound exhibits potent antitumor activity.

Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.

Gemcitabine-O-Si(di-iso)-O-Mc, a drug-linker conjugate for Antibody-Drug Conjugates (ADC), exhibits potent antitumor activity. It incorporates Gemcitabine, a pyrimidine nucleoside analog antimetabolite and antineoplastic agent, connected through the ADC linker[1].

NAMPT inhibitor-linker 2, a drug-linker conjugate for antibody-drug conjugates (ADCs), comprises an NAMPT inhibitor payload and a linker. When combined with an anti-c-Kit monoclonal antibody to form ADC-4, it demonstrates potent efficacy against c-Kit expressing cell lines, including GIST-T1 and NCI-H526, with IC50 values of <7 pM and 40 pM, respectively.

Mal-PEG4-VA-PBD is a drug-linker conjugate for Antibody-Drug Conjugates (ADCs), comprising the antitumor antibiotic Pyrrolobenzodiazepine (PBD), connected through Mal-PEG4-VA.

DM4-SPDP, a drug-linker conjugate, integrates the antitubulin agent DM4 with the linker SMCC, facilitating the creation of antibody drug conjugates[1]. Additionally, SPDP serves as a short-chain crosslinker enabling amine-to-sulfhydryl conjugation, leveraging NHS-ester and pyridyldithiol groups to establish cleavable (reducible) disulfide bonds with cysteine sulfhydryls[2][3].

DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to mitigate the systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s capabilities as an antibody-conjugatable maytansinoid.